Abstract
Tumor cell resistance to anti-cancer drugs is a major obstacle in tumor therapy. In this study, we investigated the mechanism of cordycepin-mediated resensitization to cisplatin in T24R2 cells, a T24-derived cell line. Treatment with cordycepin or cisplatin (2 μg/mL) alone failed to induce cell death in T24R2 cells, but combination treatment with these drugs significantly induced apoptosis through mitochondrial pathways, including depolarization of mitochondrial membranes, decrease in anti-apoptotic proteins Bcl-2, Bcl-xL, and Mcl-1, and increase in pro-apoptotic proteins Bak and Bax. High expression levels of MDR1 were the cause of cisplatin resistance in T24R2 cells, and cordycepin significantly reduced MDR1 expression through inhibition of MDR1 promoter activity. MDR1 promoter activity was dependent on transcription factor Ets-1 in T24R2 cells. Although correlation exists between MDR1 and Ets-1 expression in bladder cancer patients, active Ets-1, Thr38 phosphorylated form (pThr38), was critical to induce MDR1 expression. Cordycepin decreased pThr-38 Ets-1 levels and reduced MDR1 transcription, probably through its effects on PI3K signaling, inducing the resensitization of T24R2 cells to cisplatin. The results suggest that co...Continue Reading
References
Feb 27, 1997·Oncogene·C WasylykB Wasylyk
Aug 3, 2001·The Journal of Biological Chemistry·J SampathJ D Schuetz
Jun 26, 2002·BJU International·J H HongH Ahn
Oct 8, 2003·The Oncologist·Gregory D LeonardSusan E Bates
Jun 26, 2004·Blood·Daruka Mahadevan, Alan F List
Dec 28, 2004·Journal of Ethnopharmacology·So-Young Won, Eun-Hee Park
Feb 14, 2007·Cancer Metastasis Reviews·Xiu-bao Chang
Aug 19, 2007·Current Topics in Medicinal Chemistry·John Yuan WangSara Wu
Jun 11, 2010·Proceedings of the National Academy of Sciences of the United States of America·Mary L NelsonBarbara J Graves
Jan 11, 2012·Carcinogenesis·A M SmithD P Turner
Feb 22, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kevin G Chen, Branimir I Sikic
Feb 2, 2013·Current Cancer Drug Targets·Ziyad Binkhathlan, Afsaneh Lavasanifar
Mar 19, 2013·Frontiers in Pharmacology·Hiba Zahreddine, Katherine L B Borden
Aug 24, 2013·Cancer Research·Justin M BalkoCarlos L Arteaga
Oct 15, 2013·Life Sciences·Hardeep S TuliDharambir Kashyap
Mar 29, 2014·Critical Reviews in Biotechnology·Jian Dong Cui
May 3, 2014·International Journal of Oncology·I Made Winarsa RumaMasakiyo Sakaguchi
Oct 9, 2014·Nucleic Acids Research·Joshua P PlotnikPeter C Hollenhorst
Dec 3, 2014·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Shang-Min ChouTang-Long Shen
Apr 18, 2015·Cell Communication and Signaling : CCS·Nagarathinam SelvarajPeter C Hollenhorst
Aug 22, 2015·The FEBS Journal·Joseph T Opferman
Sep 24, 2015·Seminars in Cancer Biology·Jürgen Dittmer
Jan 19, 2016·Oncogene·M A TaylorC M Chresta
Feb 11, 2016·Scientific Reports·Emil AndreevDindial Ramotar
Oct 30, 2016·Current Pharmaceutical Design·Angelika Dlugosz, Anna Janecka
Sep 9, 2016·Scientific Reports·Hae Hyun JungYoung-Hyuck Im
Aug 19, 2017·Current Cancer Drug Targets·Xiaoqian YangXipeng Wang
Oct 17, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Song XuWenquan Zhou
Dec 20, 2017·Oncotarget·Xu-Wei ZhouLing-Yi Kong
Apr 13, 2018·Nature Reviews. Cancer·Robert W RobeyMichael M Gottesman
Aug 21, 2018·Current Pharmaceutical Design·Yuan LiLu Yu
Nov 10, 2018·Evidence-based Complementary and Alternative Medicine : ECAM·Su-Bin YuIn-Ryoung Kim
Oct 9, 2019·Cancer Biology & Therapy·Helei HouXiaochun Zhang
Jan 19, 2020·Molecular Cancer·Lei ZhangZhe-Sheng Chen